SCHEMBL8324748

SCHEMBL8324748

CCCNC(=O)c1ccc(OC)c(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 6/20 0.64
TAS1R1 Q7RTX1 6/20 0.64
ROCK2 O75116 1/20 0.60
HPGD P15428 1/20 0.58
CCR3 P51677 1/20 0.57
TP53 P04637 1/20 0.56
POLB P06746 1/20 0.54
GAA P10253 1/20 0.53
LMNA P02545 1/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
SMPD1 P17405 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HTT P42858 1/20 0.52
KMT2A Q03164 1/20 0.52
KCNH2 Q12809 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11760394 0.88 POLB (0.69) TAS1R3TAS1R1HPGDCCR3POLB
SCHEMBL930908 0.86 ROCK2 (0.76) ROCK2TP53POLBGAANPC1
SCHEMBL17758484 0.84 ROCK2 (0.61) ROCK2HPGDTP53POLBGAA
SCHEMBL14340547 0.84 TAS1R3 (0.64) TAS1R3TAS1R1ROCK2TP53POLB
SCHEMBL13753103 0.83 HPGD (0.73) HPGDPOLBLMNANPC1RAB9A
SCHEMBL5753081 0.82 NPC1 (0.79) ROCK2GAANPC1RAB9ASMN1; SMN2
SCHEMBL8324517 0.82 TAS1R3 (0.65) TAS1R3TAS1R1ROCK2TP53POLB
SCHEMBL6580514 0.81 ALDH1A1 (0.63) TAS1R3TAS1R1HPGDTP53GAA
SCHEMBL24073706 0.81 ROCK2 (0.58) ROCK2HPGDTP53POLBGAA
SCHEMBL30892214 0.81 POLB (0.68) ROCK2HPGDTP53POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 EP disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 WO disclosed